Role of MGMT in tumor development, progression, diagnosis, treatment and prognosis

Anticancer Research

Volumn 29, Issue 10, 2009, Pages 3759-3768

  Sharma, Soniya ^a   Salehi, Fateme ^a   Scheithauer, Bernd W ^b   Rotondo, Fabio ^a   Syro, Luis V ^c   Kovacs, Kalman ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b MAYO CLINIC   (United States)

^c HOSPITAL PABLO TOBÓN URIBE   (Colombia)

Author keywords

Alkylating agents; Cancer; Glioma; O6 methylguanine (O 6 MG); O6 methylguanine DNA methyltransferase (MGMT); Polymorphism; Promoter methylation; Review; Temozolomide (TMZ)

Indexed keywords

ALKYLATING AGENT; CARMUSTINE; CISPLATIN; DACARBAZINE; LOMEGUATRIB; LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROCARBAZINE; TEMOZOLOMIDE;

ASTROCYTOMA; BONE MARROW SUPPRESSION; BRAIN TUMOR; CANCER THERAPY; CELL DEATH; CORRELATION ANALYSIS; DNA POLYMORPHISM; ENZYME ACTIVATION; EPIGENETICS; GLIOBLASTOMA; GLIOMA; HEMATOPOIETIC CELL; HUMAN; IMMUNOHISTOCHEMISTRY; MELANOMA; METHYLATION; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; STOICHIOMETRY; TUMOR GROWTH;

CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; HUMANS; NEOPLASMS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; PROGNOSIS;

EID: 71949083197     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. Gerson SL: MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 4: 296-307, 2004. (Pubitemid 38525285)
2. 6-methylguanine-DNA-methyltransferase (MGMT) in cancer therapy. Curr Opin Pharmacol 6: 355-363, 2006.
3. Kaina B, Christmann M, Naumann S and Roos WP: MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair (Amst) 6: 1079-1099, 2007. (Pubitemid 47058389)
4. Liu L and Gerson SL: Targeted modulation of MGMT: clinical implications. Clin Cancer Res 12: 328-331, 2006. (Pubitemid 43166117)
5. Soejima H, Zhao W and Mukai T: Epigenetic silencing of the MGMT gene in cancer. Biochem Cell Biol 83: 429-437, 2005. (Pubitemid 41626761)
6. 6-alkylguanine-DNA alkyltransferase. DNA Repair (Amst) 6: 1071-1078, 2007.
7. Helleday T, Petermann E, Lundin C, Hodgson B and Sharma RA: DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 8: 193-204, 2008. (Pubitemid 351301852)
8. 6-methylguanine-DNA methyltransferase expression. Pharmacol Ther 74: 285-297, 1997.
9. Bugni JM, Han J, Tsai MS, Hunter DJ and Samson LD: Genetic association and functional studies of major polymorphic variants of MGMT. DNA Repair (Amst) 6: 1116-1126, 2007. (Pubitemid 47058395)
10. Casorelli I, Russo MT and Bignami M: Role of mismatch repair and MGMT in response to anticancer therapies. Anticancer Agents Med Chem 8: 368-380, 2008. (Pubitemid 351761422)
11. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC and Stupp R: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352: 997-1003, 2005.
12. Fujimaki T, Ishii H, Matsuno A, Arai H and Nakagomi T: Case Report: Effectiveness of interferon-beta and temozolomide combination therapy against temozolomide-refractory recurrent anaplastic astrocytoma. World J Surg Oncol 5: 89-93, 2007.
13. 6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide. Jpn J Clin Oncol 37: 897-906, 2007. (Pubitemid 351176479)
14. 6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 Cohort. J Clin Oncol 24: 3431-3437, 2006.
15. Wick A, Felsberg J, Steinbach JP, Herrlinger U, Platten M, Blaschke B, Meyermann R, Reifenberger G, Weller M and Wick W: Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol 25: 3357-3361,2007.
16. 6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. J Clin Oncol 25: 1470-1475, 2007.
17. Brandes AA, Franceschi E, Tosoni A, Blatt V, Pession A, Tallini G, Bertorelle R, Bartolini S, Calbucci F, Andreoli A, Frezza G, Leonardi M, Spagnolli F and Ermani M: MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 26: 2192-2197, 2008.
18. Weaver KD, Grossman SA and Herman JG: Methylated tumor-specific DNA as a plasma biomarker in patients with glioma. Cancer Invest 24: 35-40, 2006. (Pubitemid 43247271)
19. 6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathol 18: 520-532, 2008.
20. 6-methylguanine-DNA methyltransferase expression in supratentorial diffuse low-grade astrocytoma. Surg Neurol 68: 603-608; discussion 608-609, 2007.
21. Cankovic M, Mikkelsen T, Rosenblum ML and Zarbo RJ: A simplified laboratory validated assay for MGMT promoter hypermethylation analysis of glioma specimens from formalin-fixed paraffin-embedded tissue. Lab Invest 87: 392-397, 2007. (Pubitemid 46474563)
22. Patel R, Shervington L, Lea R and Shervington A: Epigenetic silencing of telomerase and a non-alkylating agent as a novel therapeutic approach for glioma. Brain Res 1188: 173-181, 2008.
23. Jeuken JW, Cornelissen SJ, Vriezen M, Dekkers MM, Errami A, Sijben A, Boots-Sprenger SH and Wesseling P: MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas. Lab Invest 87: 1055-1065, 2007. (Pubitemid 47429190)
24. Gilbert MR and Armstrong TS: Management of patients with newly diagnosed malignant primary brain tumors with a focus on the evolving role of temozolomide. Ther Clin Risk Manag 3: 1027-1033, 2007.
25. Preusser M, Haberler C and Hainfellner JA: Malignant glioma: neuropathology and neurobiology. Wien Med Wochenschr 156: 332-337, 2006.
26. Capper D, Mittelbronn M, Meyermann R and Schittenhelm J: Pitfalls in the assessment of MGMT expression and in its correlation with survival in diffuse astrocytomas: proposal of a feasible immunohistochemical approach. Acta Neuropathol 115: 249-259, 2008.
27. Pike BL, Greiner TC, Wang X, Weisenburger DD, Hsu YH, Renaud G, Wolfsberg TG, Kim M, Weisenberger DJ, Siegmund KD, Ye W, Groshen S, Mehrian-Shai R, Delabie J, Chan WC, Laird PW and Hacia JG: DNA methylation profiles in diffuse large B-cell lymphoma and their relationship to gene expression status. Leukemia 22: 1035-1043,2008. (Pubitemid 351689886)
28. 6-alkylguanine. Proc Natl Acad Sci USA 87: 686-690, 1990. (Pubitemid 20051435)
29. Day RS, III, Ziolkowski CHJ, Scudiero DA, Meyer SA and Mattern MR: Human tumor cell strains defective in the repair of alkylation damage. Carcinogenesis 1: 21-32, 1980.
30. Zhang D, Bai Y, Wang Y, Luo J, Ge Q, Qiao Y, Jia C and Lu Z: Detailed methylation patterns and protein expression profiles of MGMT in colorectal carcinoma surgical margins. Clin Biochem 41: 19-25, 2008. (Pubitemid 350216824)
31. Khan OA, Ranson M, Michael M, Olver I, Levitt NC, Mortimer P, Watson AJ, Margison GP, Midgley R and Middleton MR: A phase II trial of Lomeguatrib and temozolomide in metastatic colorectal cancer. Br J Cancer 95: 1614-1618, 2008. (Pubitemid 351684692)
32. 6-Methylguanine-DNA methyltransferase promoter hypermethylation in colorectal carcinogenesis. Oncol Rep 17: 1421-1427, 2007.
33. Ogino S, Hazra A, Tranah GJ, Kirkner GJ, Kawasaki T, Nosho K, Ohnishi M, Suemoto Y, Meyerhardt JA, Hunter DJ and Fuchs CS: MGMT germline polymorphism is associated with somatic MGMT promoter methylation and gene silencing in colorectal cancer. Carcinogenesis 8: 1985-1990, 2007.
34. Zaidi NH, Pretlow TP, O'Riordan MA, Dumenco LL, Allay E and Gerson SL: Transgenic expression of human MGMT protects against azoxymethane-induced aberrant crypt foci and G to A mutations in the K-ras oncogene of mouse colon. Carcinogenesis 16: 451-456, 1995.
35. Deng G, Kakar S, Tanaka H, Matsuzaki K, Miura S, Sleisenger MH and Kim YS: Proximal and distal colorectal cancers show distinct gene-specific methylation profiles and clinical and molecular characteristics. Eur J Cancer 44: 1290-1301, 2008.
36. Milsom MD and Williams DA: Live and let die: in vivo selection of gene-modified hematopoietic stem cells via MGMT-mediated chemoprotection. DNA Repair (Amst) 6: 1210-1221, 2007.
37. Cooper WA, Kohonen-Corish MR, Chan C, Kwun SY, McCaughan B, Kennedy C, Sutherland RL and Lee CS: Prognostic significance of DNA repair proteins MLH1, MSH2 and MGMT expression in non-small cell lung cancer and precursor lesions. Histopathology 52: 613-622, 2008.
38. Povey AC, Margison GP and Santibanez-Koref MF: Lung cancer risk and variation in MGMT activity and sequence. DNA Repair (Amst) 6: 1134-1144, 2007.
39. Digel W and Lubbert M: DNA methylation disturbances as novel therapeutic target in lung cancer: preclinical and clinical results. Crit Rev Oncol Hematol 55: 1-11, 2005. (Pubitemid 40779471)
40. 6-methylguanine DNA methyltransferase in the absence of promoter hypermethylation in hepatocellular carcinomas from Australia and South Africa. Oncol Rep 17: 817-822, 2007.
41. Hakem R: DNA-damage repair: the good, the bad, and the ugly. EMBO J 27: 589-605, 2008. (Pubitemid 351273123)
42. Wilson SH: Mammalian base excision repair and DNA polymerase beta. Mutat Res 407: 203-215, 1998. (Pubitemid 28275828)
43. Engelbergs J, Thomale J and Rajewsky MF: Role of DNA repair in carcinogen-induced ras mutation. Mutat Res 450: 139-153, 2000. (Pubitemid 30323639)
44. Krzesniak M, Butkiewicz D, Samojedny A, Chorazy M and Rusin M: Polymorphisms in TDG and MGMT genes - epidemiological and functional study in lung cancer patients from Poland. Ann Hum Genet 68: 300-312, 2004. (Pubitemid 39162742)
45. 6-methylguanine- DNA methyltransferase-codon 178 genetic polymorphism. Lung Cancer 44: 281-286, 2004. (Pubitemid 38609435)
46. Huang WY, Chow WH, Rothman N, Lissowska J, Llaca V, Yeager M, Zatonski W and Hayes RB: Selected DNA repair polymorphisms and gastric cancer in Poland. Carcinogenesis 26: 1354-1359, 2005. (Pubitemid 41417877)
47. 6-alkylguanine DNA alkyltransferase gene and lung cancer risk in non-smokers exposed to second-hand smoke. Cancer Epidemiol Biomarkers Prev 13: 320-323, 2004. (Pubitemid 38222567)
48. 6-alkylguanine DNA alkyltransferase gene in lung cancer risk. Cancer Epidemiol Biomarkers Prev 9: 339-342, 2000.
49. 6-methylguanine DNA methyltransferase and breast cancer risk. Pharmacogenet Genomics 16: 469-474, 2006. (Pubitemid 43922344)
50. Shen J, Terry MB, Gammon MD, Gaudet MM, Teitelbaum SL, Eng SM, Sagiv SK, Neugut AI and Santella RM: MGMT genotype modulates the associations between cigarette smoking, dietary antioxidants and breast cancer risk. Carcinogenesis 26: 2131-2137, 2005. (Pubitemid 41672201)
51. 6- methylguanine DNA methyltransferase and endometrial cancer risk. Carcinogenesis 27: 2281-2285, 2006. (Pubitemid 44644817)
52. 6-Methylguanine-DNA-methyltransferase expression and gene polymorphisms in relation to chemotherapeutic response in metastatic melanoma. Br J Cancer 89: 1517-1523, 2003. (Pubitemid 37386609)
53. Ritchey JD, Huang WY, Chokkalingam AP, Gao YT, Deng J, Levine P, Stanczyk FZ and Hsing AW: Genetic variants of DNA repair genes and prostate cancer: a population-based study. Cancer Epidemiol Biomarkers Prev 14: 1703-1709, 2005. (Pubitemid 40995083)
54. Jiao L, Bondy ML, Hassan MM, Wolff RA, Evans DB, Abbruzzese JL and Li D: Selected polymorphisms of DNA repair genes and risk of pancreatic cancer. Cancer Detect Prev 30: 284-291, 2006. (Pubitemid 44163055)
55. 6-methylguanine-DNA methyltransferase Leu84Phe and Ile143Val polymorphisms and risk of colorectal cancer in the Nurses' Health Study and Physicians' Health Study (United States). Cancer Causes Control 17: 721-731, 2006. (Pubitemid 43668331)
56. Inoue R, Isono M, Abe M, Abe T and Kobayashi H: A genotype of the polymorphic DNA repair gene MGMT is associated with de novo glioblastoma. Neurol Res 25: 875-879, 2003. (Pubitemid 37499726)
57. 6-methylguanine-DNA methyltransferase and risk of bladder cancer in southern China: a case control analysis. Cancer Lett 227: 49-57, 2005.
58. Moreno V, Gemignani F, Landi S, Gioia-Patricola L, Chabrier A, Blanco I, González S, Guino E, Capellà G and Canzian F: Polymorphisms in genes of nucleotide and base excision repair: risk and prognosis of colorectal cancer. Clin Cancer Res 12: 2101-2108, 2006.
59. 6-Methylguanine- DNA methyltransferase deficiency in developing brain: implications for brain tumorigenesis. DNA Repair (Amst) 6: 1127-1133, 2007.
60. 6-methylguanine-DNA methyltransferase in histologically normal brain adjacent to primary human brain tumors. Proc Natl Acad Sci USA 93: 6941-6946, 1996. (Pubitemid 26243479)
61. Sawhney M, Rohatgi N, Kaur J, Gupta SD, Deo SV, Shukla NK and Ralhan R: MGMT expression in oral precancerous and cancerous lesions: correlation with progression, nodal metastasis and poor prognosis. Oral Oncol 43: 515-522, 2007. (Pubitemid 46561437)
62. 6-methylguanine DNA methyltransferase gene expression without affecting promoter methylation. Biochem Pharmacol 75: 2100-2111, 2008.
63. Zochbauer-Muller S, Fong KM, Virmani AK, Geradts J, Gazdar AF and Minna JD: Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 61: 249-255, 2001. (Pubitemid 32095725)
64. Marchesi F, Turriziani M, Tortorelli G, Avvisati G, Torino F and De Vecchis L: Triazene compounds: mechanism of action and related DNA repair systems. Pharmacol Res 56: 275-287, 2007. (Pubitemid 47488901)
65. Rietschel P, Wolchok JD, Krown S, Gerst S, Jungbluth AA, Busam K, Smith K, Orlow I, Panageas K and Chapman PB: Phase II study of extended-dose temozolomide in patients with melanoma. J Clin Oncol 26: 2299-2304, 2008.
66. Kovacs K, Horvath E, Syro LV, Uribe H, Penagos LC, Ortiz LD and Fadul CE: Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: Morphological findings. Hum Pathol 38: 185-189, 2007. (Pubitemid 44880216)
67. Kovacs K, Scheithauer BW, Lombardero M, McLendon RE, Syro LV, Uribe H, Ortiz LD and Penagos LC: MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy. Acta Neuropathol 115: 261-262, 2008.
68. Syro LV, Uribe H, Penagos LC, Ortiz LD, Fadul CE, Horvath E and Kovacs K: Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm. Clin Endocrinol (Oxf) 65: 552-553, 2006. (Pubitemid 44414285)
69. Moyes VJ, Alusi G, Sabin HI, Evanson J, Berney DM, Kovacs K, Monson JP, Plowman PN and Drake WM: Treatment of Nelson's syndrome with temozolomide. Eur J Endocrinol 160: 115-119, 2009.
70. Dunn J, Baborie A, Alam F, Joyce K, Moxham M, Sibson R, Crooks D, Husband D, Shenoy A, Brodbelt A, Wong H, Liloglou T, Haylock B and Walker C: Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy. Br J Cancer 101: 124-131, 2009.
71. Glas M, Happold C, Rieger J, Wiewrodt D, Bähr O, Steinbach JP, Wick W, Kortmann RD, Reifenberger G, Weller M and Herrlinger U: Long-term survival of patients with glioblastoma treated with radiotherapy and Lomustine plus temozolomide. J Clin Oncol 27: 1257-1261, 2009.
72. 6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res 15: 338-345, 2009.
73. Kesari S, Schiff D, Drappatz J, LaFrankie D, Doherty L, Macklin EA, Muzikansky A, Santagata S, Ligon KL, Norden AD, Ciampa A, Bradshaw J, Levy B, Radakovic G, Ramakrishna N, Black PM and Wen PY: Phase II study of protracted daily temozolomide for low-grade gliomas in adults. Clin Cancer Res 15: 330-337, 2009.
74. Prados MD, Chang SM, Butowski N, DeBoer R, Parvataneni R, Carliner H, Kabuubi P, Ayers-Ringler J, Rabbitt J, Page M, Fedoroff A, Sneed PK, Berger MS, McDermott MW, Parsa AT, Vandenberg S, James CD, Lamborn KR, Stokoe D and Haas-Kogan DA: Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol 27: 579-84, 2009.
75. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO, European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups and National Cancer Institute of Canada Clinical Trials Group: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10: 459-466, 2009.
76. Brandes AA, Tosoni A, Franceschi E, Sotti G, Frezza G, Amistà P, Morandi L, Spagnolli F and Ermani M: Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation with MGMT promoter methylation status. J Clin Oncol 27: 1275-1279, 2009.
77. Augustine CK, Yoo JS, Potti A, Yoshimoto Y, Zipfel PA, Friedman HS, Nevins JR, Ali-Osman F and Tyler DS: Genomic and molecular profiling predicts response to temozolomide in melanoma. Clin Cancer Res 15: 502-510, 2009.
78. Shiraishi A, Sakumi K and Sekiguchi M: Increased susceptibility to chemotherapeutic alkylating agents of mice deficient in DNA repair methyltransferase. Carcinogenesis 21: 1879-1883, 2000.
79. Reese J, Lingas K, Ksenich P, Sweeney C, Koc O and Gerson S: Preliminary results of a phase I trial using retroviral gene transfer of G156A MGMT to protect hematopoiesis during BG and BCNU therapy of advanced malignancies (abstract 1006). Mol Ther 9: S385-S385, 2004.
80. 6-methylguanine DNA methyltransferase. Cancer Gene Ther 13: 886-895, 2006. (Pubitemid 44239133)